Core Viewpoint - The construction of China's "Blue Pharmacy" is supported by rich marine biological resources, strong research capabilities, and relatively mature results transformation, aiming to promote the high-quality development of marine drugs and biological products industry [1][5][6] Group 1: Event Overview - The 2025 Xiamen International Marine Week will be held from November 6 to 12, focusing on "creating new momentum for blue development and building a community of marine destiny" [1] - The event will integrate resources and expand dimensions, emphasizing new productive forces and promoting the upgrade of the marine economy [1] Group 2: Industry Focus - The event will focus on key areas such as marine drugs, deep-sea equipment, blue carbon sinks, and coastal tourism, facilitating industry connections through a full chain from academic discussions to project implementation [1] - A symposium on the high-quality development of marine drugs and biological products will be held to discuss the construction path of the "Blue Pharmacy" [1][5] Group 3: Research and Development - China has a vast marine area with diverse marine biological species, providing a rich resource base for drug development [2] - Institutions like the Third Institute of Oceanography and Ocean University of China have invested significantly in marine drug research, creating a comprehensive industrial technology development platform [2] Group 4: Achievements and Collaborations - In the past five years, nearly 50 achievements from the Third Institute of Oceanography have been transformed into applications, adding value of 3 billion yuan to enterprises [2] - The national policy emphasizes the development of the marine biological pharmaceutical industry, providing strong support for the "Blue Pharmacy" construction [5] Group 5: Future Outlook - During the 14th Five-Year Plan period, the marine drug and biological products industry is expected to expand significantly, contributing to the high-quality development of the marine economy [6]

Core Viewpoint - The article highlights the advancements in marine biomedicine in Qingdao, particularly focusing on the clinical trials of the marine polysaccharide drug BG136, which is the first of its kind in the world to enter clinical trials for cancer treatment [5][15]. Marine Biomedical Research - The Qingdao Marine Biomedical Research Institute aims to bridge the gap between scientific research and industrial application in marine biomedicine, promoting the transformation of research outcomes into marketable products [5][6]. - BG136, derived from Antarctic seaweed, activates the innate immune system to exert anti-tumor effects [6][15]. - The institute is also advancing other projects under the "Blue Pharmacy" initiative, including new drugs for chronic obstructive pulmonary disease (COPD) and hepatitis B, as well as an HPV treatment that has already been launched [6][15]. Industry Development - The Qingdao Marine Biomedical Research Institute is part of a broader strategy to create an integrated ecosystem for marine biomedical innovation, combining government, industry, academia, and finance [7]. - The marine biomedical industry in Qingdao is expected to exceed 38 billion yuan in output by 2024, with projections to reach a scale of 100 billion yuan by 2026 [15]. - The city has established a "4+2+4" marine industry system to foster emerging sectors, including marine pharmaceuticals and bio-products, while enhancing traditional industries [13][15]. Competitive Advantage - China's marine drug research capabilities rank among the top globally, with domestically developed marine drugs accounting for 28% of the global market [15]. - Qingdao has nurtured leading companies in the marine pharmaceutical sector, contributing to the formation of significant industry clusters in marine drugs, medical dressings, and health products [15].